Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Methylprednisolon, ATC D07AC14 für die Zeit 01.06.2026 - 31.05.2028 (zzgl. Verlängerungsoption 1x12 Monate)

Section 130a, paragraph 8, of the SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the awarding of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned substance Methylprednisolon, ATC D07AC14, DAK-Gesundheit intends to conclude discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new drug discount contracts. A discount contract under the approval model for the aforementioned substance will enter into force for the first time on 01.06.2026 and will end on 31.05.2028 (plus extension option 1x12 months). It will automatically end, regardless, with the entry into force of the exclusive contract.